TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Effectiveness of Protocol Directed Sedation Management With Non-Protocol Directed Sedation Management on Mechanically Ventilated Patients in an Australian Intensive Care Unit.
Brief Summary: Sedation is an important treatment when caring for the critically ill patient on a respirator. Adequate sedation has been found to reduce stress, promote relaxation, induce amnesia, improve the tolerance of the respirator, and generally assist nursing care. However all sedation produces side effects for the patients. The aim of this study is to measure the effectiveness of two approaches to sedation management in an Australian Intensive Care unit.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Smartcare/PS | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Smartcare/PS; Assigned to Arm(s): 1
B: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
C: Intervention Type: PROCEDURE; Name: Sedation management protocol; Assigned to Arm(s): N/A
D: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Effectiveness of Protocol Directed Sedation Management With Non-Protocol Directed Sedation Management on Mechanically Ventilated Patients in an Australian Intensive Care Unit.
Brief Summary: Sedation is an important treatment when caring for the critically ill patient on a respirator. Adequate sedation has been found to reduce stress, promote relaxation, induce amnesia, improve the tolerance of the respirator, and generally assist nursing care. However all sedation produces side effects for the patients. The aim of this study is to measure the effectiveness of two approaches to sedation management in an Australian Intensive Care unit.


Options:
A: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI
B: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Sedation management protocol; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Sedation management strategy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Study of Changing of Lifestyle by Persons in Risk of Type 2 Diabetes
Brief Summary: We know that changing lifestyle can prevent type 2 diabetes. The challenge is how to help people changing their lifestyle. We have people in 2 groups: half of them is meeting in grops of 10 persons (interventiongroup), the other ones are just visiting their doctor (controlgroup).


Options:
A: Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight.; Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
C: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care | Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: Lifestyle intervention, Behavioral: Physical activity, dietetic counselling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Control | Intervention Type: OTHER; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Physical activity, dietetic counselling; Assigned to Arm(s): Lifestyle intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate
Brief Summary: Prior to the first infusion, patients will be randomized into one of two groups (placebo or infliximab). All patients will continue to receive the same does of methotrexate (MTX) during the study as received prior to the study. The objective of the study is to evaluate the efficacy and safety result of infliximab with Korean patients in reducing clinical signs and symptoms of rheumatoid arthritis (RA) at 30 weeks following the onset of treatment and to review whether the result is comparable to the result of the ATTRACT trial.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo, Drug: DMARD Therapy | Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: etanercept, Drug: DMARD Therapy | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: DMARD Therapy; Assigned to Arm(s): Etanercept, Placebo
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: MTX | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Infliximab, Drug: MTX | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 2
C: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)
Brief Summary: This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40 (single tablet, under the brand VYTORIN in the United States) compared with Simvastatin 40 mg. As per the original protocol, if low-density lipoprotein cholesterol (LDL-C) response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped). Clinical benefit will be defined as the reduction in the risk of the occurrence of the composite endpoint of cardiovascular (CV) death, major coronary events, and stroke.


Options:
A: Arm Label: simvastatin + ezetimibe; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): simvastatin + ezetimibe
B: Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe/simvastatin, Drug: Placebo for simvastatin 40 mg | Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: Placebo for simvastatin 40 mg, Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo for simvastatin 40 mg; Assigned to Arm(s): ezetimibe/simvastatin, simvastatin | Intervention Type: DRUG; Name: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination; Assigned to Arm(s): simvastatin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)
Brief Summary: This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40 (single tablet, under the brand VYTORIN in the United States) compared with Simvastatin 40 mg. As per the original protocol, if low-density lipoprotein cholesterol (LDL-C) response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped). Clinical benefit will be defined as the reduction in the risk of the occurrence of the composite endpoint of cardiovascular (CV) death, major coronary events, and stroke.


Options:
A: Arm Label: ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe/simvastatin, Drug: Placebo for simvastatin 40 mg | Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: Placebo for simvastatin 40 mg, Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo for simvastatin 40 mg; Assigned to Arm(s): ezetimibe/simvastatin, simvastatin | Intervention Type: DRUG; Name: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination; Assigned to Arm(s): simvastatin
B: Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Drug: Extended release niacin, Drug: Simvastatin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Extended release niacin; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Combination Therapy, Monotherapy
C: Intervention Type: DRUG; Name: niacin (+) laropiprant (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: niacin (+) laropiprant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: simvastatin; Assigned to Arm(s): N/A
D: Arm Label: Extended-release niacin; Type: EXPERIMENTAL; Interventions: Drug: extended-release niacin (Niaspan) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: extended-release niacin (Niaspan) | Intervention Type: DRUG; Name: extended-release niacin (Niaspan); Assigned to Arm(s): Extended-release niacin, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Single Blind Trial of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Therapeutic Angiogenesis
Brief Summary: This is a phase 1, single-blind trial to evaluate using autologous bone marrow mononuclear stem cells in ischemic cardiomyopathy patients. The patients must have a Left Ventricular Ejection Fraction (LVEF) of less than or equal to 45%. Once the patient meets all inclusion criteria, and no exclusion criteria are found, the subject is consented for the study, and extensive baseline testing is performed at St Luke's Hospital in Houston. Once all baseline testing criteria is met, the patient has their own bone marrow harvested and later that day the subject is taken to a cardiac catheterization lab where left ventricular electromechanical mapping using NOGA software (NOGA mapping) is performed and the processed stem cells are injected under electromechanical guidance into the affected areas of the left ventricle. The patient is usually discharged home the next day and returns for follow up visits at weeks 1, 2, 4, 6, 8, 12, months 6 and 12 and for phone call follow-up at months 4, 5, 7, 8, 9, 10, 11. Patients undergo extensive testing at most of these follow-up visits, including repeat cardiac catheterization with NOGA mapping at month 6 after stem cell injection.


Options:
A: Arm Label: Placebo Injections; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Active Stem Cell Injections; Type: EXPERIMENTAL; Interventions: Biological: Adult stem cells | Intervention Type: BIOLOGICAL; Name: Adult stem cells; Assigned to Arm(s): Active Stem Cell Injections | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Injections
B: Arm Label: Stem Cell Therapy; Type: EXPERIMENTAL; Interventions: Device: Intramyocardial Injection of stem cells via NOGA Mapping | Arm Label: Control, then Stem Cell Therapy; Type: OTHER; Interventions: Other: Control, then Stem Cell Therapy | Intervention Type: DEVICE; Name: Intramyocardial Injection of stem cells via NOGA Mapping; Assigned to Arm(s): Stem Cell Therapy | Intervention Type: OTHER; Name: Control, then Stem Cell Therapy; Assigned to Arm(s): Control, then Stem Cell Therapy
C: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Biological: Sham, no injection | Arm Label: C3BS-CQR-1 Treated; Type: EXPERIMENTAL; Interventions: Biological: Injection of C3BS-CQR-1 | Intervention Type: BIOLOGICAL; Name: Injection of C3BS-CQR-1; Assigned to Arm(s): C3BS-CQR-1 Treated | Intervention Type: BIOLOGICAL; Name: Sham, no injection; Assigned to Arm(s): Control
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mesenchymal stromal cell | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline | Intervention Type: BIOLOGICAL; Name: Mesenchymal stromal cell; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Saline; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Multicenter Trial Comparing Mycophenolate Mofetil and Azathioprine as Remission-maintaining Treatment for Proliferative Lupus Glomerulonephritis. The MAINTAIN Nephritis Trial.
Brief Summary: The purpose of the study is to determine whether mycophenolate mofetil is superior to azathioprine to prevent flares of lupus nephritis.


Options:
A: Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus | Arm Label: mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil
B: Arm Label: Human Umbilical Cord derived MSCs; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord derived MSCs | Arm Label: Cyclophosphamide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord derived MSCs; Assigned to Arm(s): Human Umbilical Cord derived MSCs | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Abetimus sodium (LJP 394); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Trial of Academic Hospitalists
Brief Summary: Care of hospitalized patients by "hospitalists" -- often defined as physicians who dedicate at least 25% of their practice to inpatient care -- is a recent, growing, and controversial trend in health care delivery in the United States. But despite the growth of interest in hospitalists, there have been few scientific evaluations of the concept. The comprehensive aim of this research study is to measure and analyze the effects of hospitalists on patient outcomes, costs and medical education on the general medical services of a group of academic centers.


Options:
A: Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal intervention | Arm Label: Enhanced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Minimal intervention; Assigned to Arm(s): Minimal intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Intervention; Assigned to Arm(s): Enhanced intervention
B: Arm Label: Pharmacist service,; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist service; Assigned to Arm(s): Pharmacist service,
C: Intervention Type: BEHAVIORAL; Name: Observation (behavior); Assigned to Arm(s): N/A
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychological Intervention for Persons at Risk of Psychosis in the Early Initial Prodromal State
Brief Summary: The purpose of this randomized controlled trial is to develop a cognitive behavioral therapy (CBT) for persons with at risk mental states in the early initial prodromal state and to evaluate CBT in comparison to supportive counselling (SC).It is hypothesized that CBT is more effective than SC on transition to subthreshold psychosis, psychosis and schizophrenia as well as on prodromal symptoms and social adjustment.


Options:
A: Arm Label: Family Focused Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Family Focused Treatment | Arm Label: Enhanced Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Care | Intervention Type: BEHAVIORAL; Name: Family Focused Treatment; Assigned to Arm(s): Family Focused Treatment | Intervention Type: BEHAVIORAL; Name: Enhanced Care; Assigned to Arm(s): Enhanced Care
B: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Counselling (SC); Assigned to Arm(s): N/A
C: Arm Label: Cognitive Remediation Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Remediation Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Remediation Therapy; Assigned to Arm(s): Cognitive Remediation Therapy
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychological Intervention for Persons at Risk of Psychosis in the Early Initial Prodromal State
Brief Summary: The purpose of this randomized controlled trial is to develop a cognitive behavioral therapy (CBT) for persons with at risk mental states in the early initial prodromal state and to evaluate CBT in comparison to supportive counselling (SC).It is hypothesized that CBT is more effective than SC on transition to subthreshold psychosis, psychosis and schizophrenia as well as on prodromal symptoms and social adjustment.


Options:
A: Arm Label: Self-learning program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-learning program | Arm Label: Psycho-education (in Phase 2); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psycho-education program (in Phase 2) | Arm Label: Routine community care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-learning program; Assigned to Arm(s): Self-learning program | Intervention Type: BEHAVIORAL; Name: Psycho-education program (in Phase 2); Assigned to Arm(s): Psycho-education (in Phase 2)
B: Arm Label: Glycine; Type: EXPERIMENTAL; Interventions: Drug: Glycine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycine; Assigned to Arm(s): Glycine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Counselling (SC); Assigned to Arm(s): N/A
D: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care

Answer: C